{"title": "Novavax anuncia resultados positivos de la vacuna contra la COVID-19 en la poblaci\u00f3n pedi\u00e1trica en el ensayo cl\u00ednico PREVENT-19 de fase 3", "author": "Novavax; Inc", "url": "https://www.prnewswire.com/news-releases/novavax-anuncia-resultados-positivos-de-la-vacuna-contra-la-covid-19-en-la-poblacion-pediatrica-en-el-ensayo-clinico-prevent-19-de-fase-3-835500514.html", "hostname": "prnewswire.com", "description": "- La expansi\u00f3n pedi\u00e1trica de PREVENT-19 en adolescentes de 12 a 17 a\u00f1os logr\u00f3 el criterio de valoraci\u00f3n primario de efectividad que demuestra su comparabilidad...", "sitename": "PR Newswire", "date": "2022-02-14", "id": null, "license": null, "body": null, "comments": "Share this article", "commentsbody": null, "raw_text": null, "text": "Novavax anuncia resultados positivos de la vacuna contra la COVID-19 en la poblaci\u00f3n pedi\u00e1trica en el ensayo cl\u00ednico PREVENT-19 de fase 3\n[Novavax, Inc.](/news/novavax%2C-inc./)\n14 Feb, 2022, 07:25 ET\n[]\n- La expansi\u00f3n pedi\u00e1trica de PREVENT-19 en adolescentes de 12 a 17 a\u00f1os logr\u00f3 el criterio de valoraci\u00f3n primario de efectividad que demuestra su comparabilidad con la poblaci\u00f3n adulta\n- El ensayo demostr\u00f3 una eficacia cl\u00ednica del 82 % contra la variante delta\n- Las respuestas inmunes fueron entre dos y tres veces mayores en los adolescentes que en los adultos contra todas las variantes estudiadas\n- La vacuna fue bien tolerada y no se identificaron se\u00f1ales de seguridad\n- Novavax planea complementar las solicitudes regulatorias globales con datos pedi\u00e1tricos para el primer trimestre de 2022\n- La empresa organizar\u00e1 una teleconferencia de inversionistas el d\u00eda de hoy de 4:30 p. m.a 5:00 p. m, hora del este\nGAITHERSBURG, Maryland, 14 de febrero de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)), una empresa de biotecnolog\u00eda dedicada a desarrollar y comercializar vacunas de \u00faltima generaci\u00f3n contra enfermedades infecciosas graves, anunci\u00f3 hoy que la NVX-CoV2373, su vacuna contra la COVID-19 basada en prote\u00ednas de nanopart\u00edculas recombinantes, logr\u00f3 su criterio de valoraci\u00f3n de efectividad primario en la expansi\u00f3n pedi\u00e1trica de su ensayo pivotal de fase 3 PREVENT-19 y demostr\u00f3 una eficacia del 80 % en general en un momento en que la variante delta fue la cepa circulante predominante en los Estados Unidos. El estudio inscribi\u00f3 a 2.247 adolescentes de 12 a 17 a\u00f1os en 73 sitios de los Estados Unidos para evaluar la seguridad, la efectividad (inmunogenicidad) y la eficacia, con \u00e9nfasis en garantizar una representaci\u00f3n racial y \u00e9tnica bien equilibrada entre los participantes.\n\"Nos sentimos alentados por los resultados en esta poblaci\u00f3n adolescente debido a la continua necesidad de opciones alternativas de vacunaci\u00f3n contra la COVID-19\", afirm\u00f3 Filip Dubovsky, MD, director m\u00e9dico de Novavax. \"Creemos que la vacuna de Novavax ofrece una tecnolog\u00eda y una opci\u00f3n diferenciadas para esta poblaci\u00f3n m\u00e1s joven, gracias a su tecnolog\u00eda basada en prote\u00ednas que ya se utiliza en otras vacunas y las respuestas positivas demostradas contra las variantes\".\nEl ensayo primario PREVENT-19 pivotal de fase 3 realizado en adultos de 18 a\u00f1os o m\u00e1s, cuyos resultados se publicaron en\n[The New England Journal of Medicine](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3652379960&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D2201495428%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395363-1%2526h%253D1255159614%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DThe%252BNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DThe%2BNew%2BEngland%2BJournal%2Bof%2BMedicine&a=The+New+England+Journal+of+Medicine) (NEJM), inscribi\u00f3 a 30.000 participantes en los Estados Unidos y M\u00e9xico. La NVX-CoV2373 logr\u00f3 un 90,4 % de eficacia en general y demostr\u00f3 un perfil tranquilizador de seguridad y tolerabilidad. Los efectos adversos graves y severos en los adultos fueron escasos y mostraron un equilibrio entre el grupo que recibi\u00f3 la vacuna y el que recibi\u00f3 el placebo. Las reacciones adversas m\u00e1s comunes que se observaron en los adultos durante los estudios cl\u00ednicos (categor\u00eda de frecuencia muy com\u00fan \u2265 1/10) fueron dolor de cabeza, n\u00e1useas o v\u00f3mitos, mialgia, artralgia, sensibilidad/dolor en el sitio de la inyecci\u00f3n, fatiga y malestar. Novavax seguir\u00e1 recopilando y analizando datos del mundo real, tanto para el ensayo primario con PREVENT-19 como para la expansi\u00f3n pedi\u00e1trica, adem\u00e1s de monitorear la seguridad y la evaluaci\u00f3n de las variantes, a medida que se distribuye la vacuna.\nLa vacuna NVX-CoV2373 a\u00fan no ha sido autorizada para la poblaci\u00f3n adolescente. Novavax espera presentar sus solicitudes normativas para una indicaci\u00f3n pedi\u00e1trica en adolescentes de 12 a 17 a\u00f1os a las autoridades reguladoras globales durante el primer trimestre de 2022. Novavax tambi\u00e9n espera iniciar otros estudios a nivel mundial para evaluar a los grupos etarios m\u00e1s j\u00f3venes durante el segundo trimestre de 2022.\nHasta la fecha, NVX-CoV2373 ha recibido autorizaci\u00f3n de m\u00faltiples autoridades reguladoras en todo el mundo, incluida la autorizaci\u00f3n de comercializaci\u00f3n condicional de la\n[Comisi\u00f3n Europea](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3245167637&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D1601107271%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3432645-1%2526h%253D3389525956%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3418278-1%252526h%25253D4293825725%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3397167-1%25252526h%2525253D2118831841%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fir.novavax.com%252525252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%25252526a%2525253Dconditional%2525252Bmarketing%2525252Bauthorization%252526a%25253DEuropean%25252BUnion%2526a%253DEuropean%252BUnion%26a%3DEuropean%2BCommission&a=Comisi%C3%B3n+Europea), la [Agencia Reguladora de Medicamentos y Productos Sanitarios](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2811542486&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D2438596594%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-03-Medicines-and-Healthcare-Products-Regulatory-Agency-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine-in-Great-Britain%26a%3DMedicines%2Band%2BHealthcare%2Bproducts%2BRegulatory%2BAgency&a=Agencia+Reguladora+de+Medicamentos+y+Productos+Sanitarios) y la inclusi\u00f3n en la lista de usos de emergencia (EUL) de la [Organizaci\u00f3n Mundial de la Salud](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2819954396&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D757336834%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3432645-1%2526h%253D2742482411%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3418278-1%252526h%25253D3156131270%252526u%25253Dhttps%2525253A%2525252F%2525252Fir.novavax.com%2525252F2021-12-20-World-Health-Organization-Grants-Second-Emergency-Use-Listing-for-Novavax-COVID-19-Vaccine%252526a%25253DWorld%25252BHealth%25252BOrganization%2526a%253DWorld%252BHealth%252BOrganization%26a%3DWorld%2BHealth%2BOrganization&a=Organizaci%C3%B3n+Mundial+de+la+Salud) (WHO). Con la EUL de la OMS, existe la oportunidad de obtener autorizaci\u00f3n en m\u00e1s de 170 pa\u00edses con un potencial alcance de m\u00e1s de 6.000 millones de vidas. En este momento la vacuna tambi\u00e9n est\u00e1 siendo revisada por diferentes organismos reguladores en todo el mundo, incluida la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA).\nResultados: Eficacia cl\u00ednica consistente entre participantes adolescentes y adultos\nEn el estudio controlado con placebo y ciego, los participantes adolescentes fueron aleatorizados en proporci\u00f3n 2:1 para recibir la vacuna activa o el placebo. Los participantes del estudio fueron sometidos a un cruce ciego al material de estudio alternativo despu\u00e9s de que se recogieran los datos de seguridad necesarios para garantizar que todos los participantes recibieran la vacuna activa. Durante el per\u00edodo de observaci\u00f3n controlada con placebo, la NVX-CoV2373 demostr\u00f3 una eficacia protectora general del 79,5 % (IC 95%: 46,8, 92,1) contra la COVID-19. La eficacia fue constante en todos los grupos etarios, y todos los casos observados en el grupo que recibi\u00f3 la vacuna fueron leves seg\u00fan como lo define el protocolo del ensayo.\nLos criterios de valoraci\u00f3n de eficacia se acumularon entre el 24 de mayo y el 27 de septiembre de 2021, un momento en que la variante delta fue la cepa predominante en los Estados Unidos, con una alta transmisi\u00f3n y gravedad de la enfermedad. Se dispone de datos de la secuencia de 11 de los 20 casos confirmados, de los cuales se determin\u00f3 que el 100 % eran causados por la variante delta. La eficacia de la vacuna contra la variante delta fue del 82,0 % (IC 95%: 32,4, 95,2).\nResultados: respuesta consistente a las variantes\nLos datos de la expansi\u00f3n pedi\u00e1trica de PREVENT-19 mostraron en an\u00e1lisis post hoc respuestas inmunes s\u00f3lidas en adolescentes, incluyendo respuestas de IgG contra prote\u00ednas de espiga de varias variantes (entre ellas, la alfa, beta, delta, gamma, mu y \u00f3micron) que fueron de 2 a 3 veces mayores que en los adultos, con una seroconversi\u00f3n del 100 % contra todas las variantes despu\u00e9s de una serie de dos dosis de vacunas. Las respuestas inmunes funcionales de los adolescentes (inhibici\u00f3n del receptor hACE2) contra estas variantes fueron de 2,4 a 4 veces mayores que en los adultos contra todas las variantes evaluadas.\nResultados: un perfil tranquilizador de seguridad y reactogenicidad\nLos datos preliminares de seguridad de la expansi\u00f3n pedi\u00e1trica de PREVENT-19 mostraron que la vacuna es en general bien tolerada. Los acontecimientos adversos graves y severos fueron escasos en n\u00famero y equilibrados entre el grupo al que se le administr\u00f3 la vacuna y el que recibi\u00f3 el placebo, y no se consideraron relacionados con la vacuna. La reactogenicidad local y sist\u00e9mica fue generalmente menor o similar a la de los adultos despu\u00e9s de la primera y la segunda dosis. Las reacciones adversas m\u00e1s comunes observadas fueron sensibilidad/dolor en el sitio de la inyecci\u00f3n, dolor de cabeza, mialgia, fatiga y malestar. No hubo aumento de la reactogenicidad en los adolescentes m\u00e1s j\u00f3venes (de 12 a <15 a\u00f1os) en comparaci\u00f3n con los mayores (de 15 a <18 a\u00f1os). No se observ\u00f3 ninguna se\u00f1al de seguridad en la porci\u00f3n del estudio que fue controlada con placebo.\nCriterios de valoraci\u00f3n del estudio\nLa expansi\u00f3n pedi\u00e1trica de PREVENT-19 logr\u00f3 su criterio de valoraci\u00f3n primario de efectividad (inmunogenicidad), con respuestas de anticuerpos neutralizantes no inferiores a las observadas en adultos j\u00f3venes (de 18 a 26 a\u00f1os) participantes de PREVENT-19. Las respuestas de anticuerpos neutralizantes en los adolescentes utilizando el SARS-CoV-2 de tipo silvestre fueron aproximadamente 1,5 veces mayores en los adolescentes que en los adultos j\u00f3venes, lo que cumpli\u00f3 con los criterios especificados por la FDA.\nAcerca de PREVENT-19\nPREVENT-19 (PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19 (\"Ensayo de eficacia de la vacuna de subunidad de prote\u00edna de prefusi\u00f3n) es un estudio 2:1 aleatorizado, controlado por placebo y ciego para el observador que busca evaluar la eficacia, la seguridad y la inmunogenicidad de NVX-CoV2373 con el adyuvante Matrix-M\u2122 en 29.960 participantes de 18 a\u00f1os de edad y mayores en 119 puntos de Estados Unidos y M\u00e9xico en comparaci\u00f3n con el uso de placebo. La expansi\u00f3n pedi\u00e1trica de PREVENT-19 es un estudio 2:1 aleatorizado, controlado por placebo y ciego para el observador que busca evaluar la seguridad, efectividad y eficacia de NVX-CoV2373 con el adyuvante Matrix-M\u2122 en 2.247 participantes adolescentes de 12 a 17 a\u00f1os de edad en 73 ubicaciones de Estados Unidos en comparaci\u00f3n con el uso de placebo.\nEl estudio PREVENT-19 se lleva a cabo con apoyo del Gobierno de Estados Unidos, incluido el Departamento de Defensa, la Autoridad de Investigaci\u00f3n y Desarrollo Avanzado Biom\u00e9dico (BARDA), parte de la Oficina del Subsecretario de Preparaci\u00f3n y Respuesta del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) y el Instituto Nacional de Alergias y Enfermedades Infecciosas (NIAID), parte de los Institutos Nacionales de Salud (NIH) del HHS. BARDA aporta hasta USD 1.750 millones en virtud de un acuerdo con el Departamento de Defensa.\nTeleconferencia\nNovavax organizar\u00e1 una conferencia para inversionistas hoy a las 4:30 p. m., hora del este. Los n\u00fameros de acceso a la conferencia son (877) 870-4263 (nacional) o (412) 317-0790 (internacional). Se pedir\u00e1 a los participantes que soliciten unirse a la llamada de Novavax, Inc. Habr\u00e1 una repetici\u00f3n de la conferencia disponible desde el 10 de febrero de 2022 a las 7:30 p. m., hora del este, hasta el 17 de febrero de 2022 a las 11:59 p. m., hora del este. Para acceder a la repetici\u00f3n por tel\u00e9fono, marque (877) 344-7529 (nacional) o (412) 317-0088 (internacional) y use el c\u00f3digo de acceso 3932770.\nAsimismo, puede ver un webcast de la conferencia en el sitio web de Novavax en\n[novavax.com/events](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2707595385&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D1829805745%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3398108-1%2526h%253D1075217627%2526u%253Dhttps%25253A%25252F%25252Fprotect-us.mimecast.com%25252Fs%25252F0gHHC82A7pCjjZZvcwd3d-%25253Fdomain%25253Dnovavax.com%2526a%253Dnovavax.com%25252Fevents%26a%3Dnovavax.com%252Fevents&a=novavax.com%2Fevents). Hasta el 10 de mayo de 2022 estar\u00e1 disponible una repetici\u00f3n del webcast en el sitio web de Novavax.\nAcerca de la NVX-CoV2373\nLa NVX-CoV2373 es una vacuna basada en prote\u00ednas dise\u00f1ada a partir de la secuencia gen\u00e9tica de la primera cepa del SARS-CoV-2, el virus que causa la enfermedad COVID-19. NVX-CoV2373 fue creada utilizando la tecnolog\u00eda de nanopart\u00edculas recombinantes de Novavax para generar ant\u00edgenos derivados de la prote\u00edna espiga (S) del coronavirus y est\u00e1 formulada con Matrix-M\u2122, el adyuvante basado en saponinas patentado de Novavax, para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes. NVX-CoV2373 contiene ant\u00edgenos de prote\u00edna purificados y no puede replicarse ni causar COVID-19.\nLa vacuna de Novavax contra la COVID-19 se empaqueta como una formulaci\u00f3n l\u00edquida lista para su uso en un vial que contiene diez dosis. El r\u00e9gimen de vacunaci\u00f3n consiste en dos dosis de 0,5 ml (5 mcg de ant\u00edgeno y 50 mcg del adyuvante Matrix-M\u2122) administradas por v\u00eda intramuscular con un intervalo de 21 d\u00edas. La vacuna se almacena en un rango de temperatura entre 2 y 8 \u00b0C, lo que permite el uso de los canales de suministro de vacunas y de la cadena de fr\u00edo existentes. El uso de la vacuna est\u00e1 sujeto a las recomendaciones oficiales.\nNovavax ha formado alianzas para la fabricaci\u00f3n, comercializaci\u00f3n y distribuci\u00f3n de la NVX-CoV2373 en todo el mundo. Las autorizaciones existentes aprovechan la alianza de fabricaci\u00f3n de Novavax con Serum Institute of India (SII), el fabricante de vacunas m\u00e1s grande del mundo en cuanto a volumen. M\u00e1s adelante se complementar\u00e1 con datos de otras plantas de fabricaci\u00f3n en la cadena de suministro global de Novavax.\nAcerca de los ensayos de Fase 3 de NVX-CoV2373\nNVX-CoV2373 est\u00e1 en evaluaci\u00f3n mediante dos ensayos pivotales de Fase 3.\nPREVENT-19, un ensayo llevado a cabo en los Estados Unidos y M\u00e9xico que inscribi\u00f3 a casi 30.000 participantes de 18 a\u00f1os y m\u00e1s, logr\u00f3 una eficacia general del 90,4 %. Fue dise\u00f1ado como un estudio aleatorizado 2:1, controlado con placebo y de evaluaci\u00f3n enmascarada con el objetivo de evaluar la eficacia, seguridad e inmunogenicidad de la NVX-CoV2373. El criterio de valoraci\u00f3n primario de PREVENT-19 fue la primera aparici\u00f3n de COVID-19 sintom\u00e1tica confirmada por PCR (leve, moderada o grave) con inicio al menos 7 d\u00edas despu\u00e9s de la aplicaci\u00f3n de la segunda dosis en participantes adultos seronegativos (al SARS-CoV-2) al inicio del estudio. El criterio de \u00e9xito estad\u00edstico incluy\u00f3 un l\u00edmite inferior de 95 % IC >30 %. Un criterio de valoraci\u00f3n secundario fue la prevenci\u00f3n de la COVID-19 sintom\u00e1tica moderada o grave confirmada por PCR. Ambos criterios de valoraci\u00f3n fueron evaluados al menos siete d\u00edas despu\u00e9s de la segunda vacuna del estudio en voluntarios que no se hab\u00edan infectado previamente con el SARS-CoV-2. En general, fue bien tolerada y provoc\u00f3 una s\u00f3lida respuesta de anticuerpos tras la segunda dosis en ambos estudios. Los resultados completos del ensayo se publicaron en el\n[New England Journal of Medicine](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3162182553&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D467849857%26u%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2116185%253Fquery%253Dfeatured_home%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine) (NEJM).\nUn ensayo realizado en el Reino Unido con 14.039 participantes de 18 a\u00f1os o m\u00e1s fue dise\u00f1ado como un estudio aleatorizado, controlado con placebo y ciego para el observador, y logr\u00f3 una eficacia general del 89,7 %. El criterio de valoraci\u00f3n primario se bas\u00f3 en la primera aparici\u00f3n de COVID-19 sintom\u00e1tica confirmada por PCR (leve, moderada o grave), con inicio al menos 7 d\u00edas despu\u00e9s de la aplicaci\u00f3n de la segunda vacuna del estudio en participantes adultos serol\u00f3gicamente negativos (al SARS-CoV-2) al inicio del estudio. Los resultados completos del ensayo se publicaron en\n[NEJM](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=1609678534&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D3617137863%26u%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2107659%26a%3DNEJM&a=NEJM).\nAcerca del adyuvante Matrix-M\u2122\nEl adyuvante Matrix-M\u2122 basado en saponina patentado de Novavax ha demostrado un efecto potente y bien tolerado en general al estimular la entrada de c\u00e9lulas que presentan ant\u00edgenos en el sitio de la inyecci\u00f3n y mejorar la presentaci\u00f3n de ant\u00edgenos en los ganglios linf\u00e1ticos locales, lo que potencia la respuesta inmune.\nAcerca de Novavax\nNovavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)) es una compa\u00f1\u00eda de biotecnolog\u00eda que promueve la mejora de la salud a nivel mundial mediante el descubrimiento, el desarrollo y la comercializaci\u00f3n de vacunas innovadoras para prevenir enfermedades infecciosas graves. La plataforma de tecnolog\u00eda recombinante patentada de la compa\u00f1\u00eda aprovecha el poder y la velocidad de la ingenier\u00eda gen\u00e9tica para producir de manera eficiente nanopart\u00edculas altamente inmunog\u00e9nicas dise\u00f1adas para atender las necesidades urgentes de salud en todo el mundo. NVX-CoV2373, la vacuna contra la COVID-19 de la empresa, ha recibido autorizaci\u00f3n condicional de m\u00faltiples autoridades regulatorias a nivel mundial, incluida la Comisi\u00f3n Europea y la Organizaci\u00f3n Mundial de la Salud. La vacuna tambi\u00e9n est\u00e1 siendo revisada por diferentes organismos reguladores de todo el mundo. Adem\u00e1s de su vacuna contra la COVID-19, Novavax est\u00e1 adem\u00e1s evaluando una vacuna combinada contra la influenza estacional y la COVID en un ensayo cl\u00ednico de fase 1/2 que combina NVX-CoV2373 con NanoFlu, su candidata a vacuna tetravalente contra la influenza. Esas vacunas candidatas incorporan el adyuvante Matrix-M\u2122 basado en saponina patentado de Novavax para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes.\nPara obtener m\u00e1s informaci\u00f3n, visite\n[www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2486382758&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D3964594936%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395501-1%2526h%253D2463599076%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3392093-1%252526h%25253D203886192%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3387216-1%25252526h%2525253D3917401194%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3260461-1%2525252526h%252525253D2897486098%2525252526u%252525253Dhttp%25252525253A%25252525252F%25252525252Fwww.novavax.com%25252525252F%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com) y con\u00e9ctese con nosotros en\nDeclaraciones prospectivas\nLas declaraciones aqu\u00ed contenidas relacionadas con el futuro de Novavax, sus planes y perspectivas operacionales, sus alianzas, el desarrollo en curso de NVX-CoV2373, incluidos los planes de Novavax para iniciar estudios globales adicionales en el primer trimestre de 2022, el alcance, los plazos y los resultados de futuras solicitudes y acciones normativas, como los planes de Novavax para complementar las presentaciones regulatorias globales con los datos pedi\u00e1tricos en el primer trimestre de 2022 y la oportunidad de autorizaci\u00f3n en m\u00e1s de 170 pa\u00edses, el potencial impacto y el alcance de Novavax y NVX-CoV2373 para atender el acceso a la vacuna, controlar la pandemia y proteger las poblaciones, as\u00ed como la eficacia, la seguridad y el uso esperado de NVX-CoV2373, constituyen declaraciones prospectivas. Novavax advierte que estas declaraciones prospectivas est\u00e1n sujetas a numerosos riesgos e incertidumbres que podr\u00edan causar que los resultados reales difieran sustancialmente de los expresados o impl\u00edcitos por dichas declaraciones. Estos riesgos e incertidumbres incluyen desaf\u00edos que satisfacen, por s\u00ed solos o junto con sus socios, varios requerimientos de seguridad, eficacia y caracterizaci\u00f3n de productos, incluidos los que se relacionan con la calificaci\u00f3n del proceso y la validaci\u00f3n del ensayo, necesarios para satisfacer a las autoridades reguladoras correspondientes; la dificultad para obtener materias primas y suministros escasos; limitaciones de recursos, incluido el capital humano y la capacidad de fabricaci\u00f3n, sobre la capacidad de Novavax para seguir v\u00edas regulatorias planificadas; dificultades para cumplir los requerimientos contractuales en virtud de acuerdos con diversas entidades comerciales, gubernamentales y de otros tipos; y los dem\u00e1s factores de riesgo identificados en las secciones \"Risk Factors\" (\"Factores de riesgo\") y \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" (\"An\u00e1lisis y discusi\u00f3n de la gerencia sobre la condici\u00f3n financiera y los resultados de las operaciones\") del informe anual de Novavax en el Formulario 10-K para el a\u00f1o finalizado el 31 de diciembre de 2020 y en los informes trimestrales subsiguientes en el Formulario 10-Q presentados ante la Comisi\u00f3n de Bolsa y Valores (SEC). Les advertimos a los inversionistas no fiarse demasiado de las declaraciones prospectivas contenidas en este comunicado de prensa. Le recomendamos leer nuestros archivos registrados ante la SEC, disponibles en\n[www.sec.gov](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3701513667&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D107092519%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov) y [www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=178454868&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D56116919%26u%3Dhttp%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com), para analizar estos y otros riesgos e incertidumbres. Las declaraciones prospectivas contenidas en este comunicado de prensa se refieren solamente a la fecha en que este documento fue emitido y no estamos obligados a actualizar ni revisar ninguna de dichas declaraciones. Nuestro negocio est\u00e1 sujeto a riesgos e incertidumbres sustanciales, incluidos aquellos mencionados anteriormente. Los inversionistas actuales y potenciales, y otros interesados deben considerar cuidadosamente estos riesgos e incertidumbres.\nContactos:\nInversionistas\nNovavax, Inc.\nErika Schultz | 240-268-2022\n[[email protected]](/cdn-cgi/l/email-protection#dbb2a99bb5b4adbaadbaa3f5b8b4b6)\nSolebury Trout\nAlexandra Roy | 617-221-9197\n[[email protected]](/cdn-cgi/l/email-protection#a5c4d7cadce5d6cac9c0c7d0d7dcd1d7cad0d18bc6cac8)\nMedios\nAli Chartan | 240-720-7804\nLaura Keenan Lindsey | 202-709-7521\n[[email protected]](/cdn-cgi/l/email-protection#e18c84858880a18f8e9780978099cf828e8c)\nLogotipo:\n[https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg](https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=519295000&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D2800990811%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg)\nFUENTE Novavax, Inc.\nSOURCE Novavax, Inc.", "language": null, "image": "https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg?p=facebook", "pagetype": "articles", "links": ["/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "https://portal.prnewswire.com/Login.aspx", "https://www.prnewswire.com/account/online-membership-form/", "https://gdpr.cision.com/", "https://portal.prnewswire.com/Login.aspx", "/", "/news-releases/", "/products/overview/", "/contact-us/", "#", "/news-releases/", "/news-releases/news-releases-list/", "/news-releases/all-public-company-news/", "/news-releases/english-releases/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/multimedia/multimedia-list/", "/news-releases/photos/photos-list/", "/news-releases/videos/videos-list/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/latest-news-topics/", "#", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/automotive-transportation-latest-news/aerospace-defense-list/", "/news-releases/automotive-transportation-latest-news/air-freight-list/", "/news-releases/automotive-transportation-latest-news/airlines-aviation-list/", "/news-releases/automotive-transportation-latest-news/automotive-list/", "/news-releases/automotive-transportation-latest-news/maritime-shipbuilding-list/", "/news-releases/automotive-transportation-latest-news/railroads-and-intermodal-transportation-list/", "/news-releases/automotive-transportation-latest-news/supply-chain-logistics-list/", "/news-releases/automotive-transportation-latest-news/transportation-trucking-railroad-list/", "/news-releases/automotive-transportation-latest-news/travel-list/", "/news-releases/automotive-transportation-latest-news/trucking-and-road-transportation-list/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/business-technology-latest-news/blockchain-list/", "/news-releases/business-technology-latest-news/broadcast-tech-list/", "/news-releases/business-technology-latest-news/computer-electronics-list/", "/news-releases/business-technology-latest-news/computer-hardware-list/", "/news-releases/business-technology-latest-news/computer-software-list/", "/news-releases/business-technology-latest-news/data-analytics-list/", "/news-releases/business-technology-latest-news/electronic-commerce-list/", "/news-releases/business-technology-latest-news/electronic-components-list/", "/news-releases/business-technology-latest-news/electronic-design-automation-list/", "/news-releases/business-technology-latest-news/financial-technology-list/", "/news-releases/business-technology-latest-news/high-tech-security-list/", "/news-releases/business-technology-latest-news/internet-technology-list/", "/news-releases/business-technology-latest-news/nanotechnology-list/", "/news-releases/business-technology-latest-news/networks-list/", "/news-releases/business-technology-latest-news/peripherals-list/", "/news-releases/business-technology-latest-news/semiconductors-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/financial-services-latest-news/accounting-news-issues-list/", "/news-releases/financial-services-latest-news/acquisitions-mergers-and-takeovers-list/", "/news-releases/financial-services-latest-news/banking-financial-services-list/", "/news-releases/financial-services-latest-news/bankruptcy-list/", "/news-releases/financial-services-latest-news/bond-stock-ratings-list/", "/news-releases/financial-services-latest-news/conference-call-announcements-list/", "/news-releases/financial-services-latest-news/contracts-list/", "/news-releases/financial-services-latest-news/cryptocurrency-list/", "/news-releases/financial-services-latest-news/dividends-list/", "/news-releases/financial-services-latest-news/earnings-list/", "/news-releases/financial-services-latest-news/earnings-forecasts-projections-list/", "/news-releases/financial-services-latest-news/financing-agreements-list/", "/news-releases/financial-services-latest-news/insurance-list/", "/news-releases/financial-services-latest-news/investment-opinions-list/", "/news-releases/financial-services-latest-news/joint-ventures-list/", "/news-releases/financial-services-latest-news/mutual-funds-list/", "/news-releases/financial-services-latest-news/private-placement-list/", "/news-releases/financial-services-latest-news/real-estate-list/", "/news-releases/financial-services-latest-news/restructuring-recapitalization-list/", "/news-releases/financial-services-latest-news/sales-reports-list/", "/news-releases/financial-services-latest-news/shareholder-activism-list/", "/news-releases/financial-services-latest-news/shareholder-meetings-list/", "/news-releases/financial-services-latest-news/stock-offering-list/", "/news-releases/financial-services-latest-news/stock-split-list/", "/news-releases/financial-services-latest-news/venture-capital-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "/news-releases/general-business-latest-news/awards-list/", "/news-releases/general-business-latest-news/commercial-real-estate-list/", "/news-releases/general-business-latest-news/corporate-expansion-list/", "/news-releases/general-business-latest-news/earnings-list/", "/news-releases/general-business-latest-news/environmental-social-governance-list/", "/news-releases/general-business-latest-news/human-resource-workforce-management-list/", "/news-releases/general-business-latest-news/licensing-list/", "/news-releases/general-business-latest-news/new-products-services-list/", "/news-releases/general-business-latest-news/obituaries-list/", "/news-releases/general-business-latest-news/outsourcing-businesses-list/", "/news-releases/general-business-latest-news/overseas-real-estate-list/", "/news-releases/general-business-latest-news/personnel-announcements-list/", "/news-releases/general-business-latest-news/real-estate-transactions-list/", "/news-releases/general-business-latest-news/residential-real-estate-list/", "/news-releases/general-business-latest-news/small-business-services-list/", "/news-releases/general-business-latest-news/socially-responsible-investing-list/", "/news-releases/general-business-latest-news/surveys-polls-and-research-list/", "/news-releases/general-business-latest-news/trade-show-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "#", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/consumer-technology-latest-news/artificial-intelligence-list/", "/news-releases/consumer-technology-latest-news/blockchain-list/", "/news-releases/consumer-technology-latest-news/cloud-computing-internet-of-things-list/", "/news-releases/consumer-technology-latest-news/computer-electronics-list/", "/news-releases/consumer-technology-latest-news/computer-hardware-list/", "/news-releases/consumer-technology-latest-news/computer-software-list/", "/news-releases/consumer-technology-latest-news/consumer-electronics-list/", "/news-releases/consumer-technology-latest-news/cryptocurrency-list/", "/news-releases/consumer-technology-latest-news/data-analytics-list/", "/news-releases/consumer-technology-latest-news/electronic-commerce-list/", "/news-releases/consumer-technology-latest-news/electronic-gaming-list/", "/news-releases/consumer-technology-latest-news/financial-technology-list/", "/news-releases/consumer-technology-latest-news/mobile-entertainment-list/", "/news-releases/consumer-technology-latest-news/multimedia-internet-list/", "/news-releases/consumer-technology-latest-news/peripherals-list/", "/news-releases/consumer-technology-latest-news/social-media-list/", "/news-releases/consumer-technology-latest-news/science-tech-engineering-math-list/", "/news-releases/consumer-technology-latest-news/supply-chain-logistics-list/", "/news-releases/consumer-technology-latest-news/wireless-communications-list/", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/energy-latest-news/alternative-energies-list/", "/news-releases/energy-latest-news/chemical-list/", "/news-releases/energy-latest-news/electrical-utilities-list/", "/news-releases/energy-latest-news/gas-list/", "/news-releases/energy-latest-news/general-manufacturing-list/", "/news-releases/energy-latest-news/mining-list/", "/news-releases/energy-latest-news/mining-metals-list/", "/news-releases/energy-latest-news/oil-energy-list/", "/news-releases/energy-latest-news/oil-and-gas-discoveries-list/", "/news-releases/energy-latest-news/utilities-list/", "/news-releases/energy-latest-news/water-utilities-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/environment-latest-news/conservation-recycling-list/", "/news-releases/environment-latest-news/environmental-issues-list/", "/news-releases/environment-latest-news/environmental-policy-list/", "/news-releases/environment-latest-news/environmental-products-services-list/", "/news-releases/environment-latest-news/green-technology-list/", "/news-releases/environment-latest-news/natural-disasters/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/aerospace-defense-list/", "/news-releases/heavy-industry-manufacturing-latest-news/agriculture-list/", "/news-releases/heavy-industry-manufacturing-latest-news/chemical-list/", "/news-releases/heavy-industry-manufacturing-latest-news/construction-building-list/", "/news-releases/heavy-industry-manufacturing-latest-news/general-manufacturing-list/", "/news-releases/heavy-industry-manufacturing-latest-news/hvac-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machinery-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machine-tools-metalworking-and-metallury-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/paper-forest-products-containers-list/", "/news-releases/heavy-industry-manufacturing-latest-news/precious-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/textiles-list/", "/news-releases/heavy-industry-manufacturing-latest-news/tobacco-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "/news-releases/telecommunications-latest-news/carriers-and-services-list/", "/news-releases/telecommunications-latest-news/mobile-entertainment-list/", "/news-releases/telecommunications-latest-news/networks-list/", "/news-releases/telecommunications-latest-news/peripherals-list/", "/news-releases/telecommunications-latest-news/telecommunications-equipment-list/", "/news-releases/telecommunications-latest-news/telecommunications-industry-list/", "/news-releases/telecommunications-latest-news/voip-list/", "/news-releases/telecommunications-latest-news/wireless-communications-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "#", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/consumer-products-retail-latest-news/animals-pets-list/", "/news-releases/consumer-products-retail-latest-news/beers-wines-and-spirits-list/", "/news-releases/consumer-products-retail-latest-news/beverages-list/", "/news-releases/consumer-products-retail-latest-news/bridal-services-list/", "/news-releases/consumer-products-retail-latest-news/cannabis-list/", "/news-releases/consumer-products-retail-latest-news/cosmetics-and-personal-care-list/", "/news-releases/consumer-products-retail-latest-news/fashion-list/", "/news-releases/consumer-products-retail-latest-news/food-beverages-list/", "/news-releases/consumer-products-retail-latest-news/furniture-and-furnishings-list/", "/news-releases/consumer-products-retail-latest-news/home-improvements-list/", "/news-releases/consumer-products-retail-latest-news/household-consumer-cosmetics-list/", "/news-releases/consumer-products-retail-latest-news/household-products-list/", "/news-releases/consumer-products-retail-latest-news/jewelry-list/", "/news-releases/consumer-products-retail-latest-news/non-alcoholic-beverages-list/", "/news-releases/consumer-products-retail-latest-news/office-products-list/", "/news-releases/consumer-products-retail-latest-news/organic-food-list/", "/news-releases/consumer-products-retail-latest-news/product-recalls-list/", "/news-releases/consumer-products-retail-latest-news/restaurants-list/", "/news-releases/consumer-products-retail-latest-news/retail-list/", "/news-releases/consumer-products-retail-latest-news/supermarkets-list/", "/news-releases/consumer-products-retail-latest-news/toys-list/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/health-latest-news/biometrics-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/clinical-trials-medical-discoveries-list/", "/news-releases/health-latest-news/dentistry-list/", "/news-releases/health-latest-news/fda-approval-list/", "/news-releases/health-latest-news/fitness-wellness-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/health-insurance-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/international-medical-approval-list/", "/news-releases/health-latest-news/medical-equipment-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/mental-health-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/supplementary-medicine-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/sports-latest-news/general-sports-list/", "/news-releases/sports-latest-news/outdoors-camping-hiking-list/", "/news-releases/sports-latest-news/sporting-events-list/", "/news-releases/sports-latest-news/sports-equipment-accessories-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "/news-releases/travel-latest-news/amusement-parks-and-tourist-attractions-list/", "/news-releases/travel-latest-news/gambling-casinos-list/", "/news-releases/travel-latest-news/hotels-and-resorts-list/", "/news-releases/travel-latest-news/leisure-tourism-list/", "/news-releases/travel-latest-news/outdoors-camping-hiking-list/", "/news-releases/travel-latest-news/passenger-aviation-list/", "/news-releases/travel-latest-news/travel-industry-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "#", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "/news-releases/policy-public-interest-latest-news/advocacy-group-opinion-list/", "/news-releases/policy-public-interest-latest-news/animal-welfare-list/", "/news-releases/policy-public-interest-latest-news/congressional-presidential-campaigns-list/", "/news-releases/policy-public-interest-latest-news/corporate-social-responsibility-list/", "/news-releases/policy-public-interest-latest-news/domestic-policy-list/", "/news-releases/policy-public-interest-latest-news/economic-news-trends-analysis-list/", "/news-releases/policy-public-interest-latest-news/education-list/", "/news-releases/policy-public-interest-latest-news/environmental-list/", "/news-releases/policy-public-interest-latest-news/european-government-list/", "/news-releases/policy-public-interest-latest-news/fda-approval-list/", "/news-releases/policy-public-interest-latest-news/federal-and-state-legislation-list/", "/news-releases/policy-public-interest-latest-news/federal-executive-branch-agency-news-list/", "/news-releases/policy-public-interest-latest-news/foreign-policy-international-affairs-list/", "/news-releases/policy-public-interest-latest-news/homeland-security-list/", "/news-releases/policy-public-interest-latest-news/labor-union-news-list/", "/news-releases/policy-public-interest-latest-news/legal-issues-list/", "/news-releases/policy-public-interest-latest-news/natural-disasters-list/", "/news-releases/policy-public-interest-latest-news/not-for-profit-list/", "/news-releases/policy-public-interest-latest-news/patent-law-list/", "/news-releases/policy-public-interest-latest-news/public-safety-list/", "/news-releases/policy-public-interest-latest-news/trade-policy-list/", "/news-releases/policy-public-interest-latest-news/us-state-policy-news-list/", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "#", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/news-releases/multicultural-latest-news/native-american-list/", "/news-releases/multicultural-latest-news/african-american-related-news-list/", "/news-releases/multicultural-latest-news/asian-related-news-list/", "/news-releases/multicultural-latest-news/children-related-news-list/", "/news-releases/multicultural-latest-news/diversity-equity-inclusion/", "/news-releases/multicultural-latest-news/hispanic-oriented-news-list/", "/news-releases/multicultural-latest-news/lesbian-gay-bisexual-list/", "/news-releases/multicultural-latest-news/mens-interest-list/", "/news-releases/multicultural-latest-news/people-with-disabilities-list/", "/news-releases/multicultural-latest-news/religion-list/", "/news-releases/multicultural-latest-news/senior-citizens-list/", "/news-releases/multicultural-latest-news/veterans-list/", "/news-releases/multicultural-latest-news/women-related-news-list/", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/ae/ar/news-releases/", "/comunicados-de-prensa/", "/comunicados-para-a-imprensa/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/de/pressemitteilungen/", "/es/comunicados-de-prensa/", "/fr/communiques-de-presse/", "/it/comunicati-stampa/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/fi/lehdistotiedotteet/", "/sv/pressmeddelanden/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/guaranteed-paid-placement/", "/products/all-products/", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "#nav-mobile", "/", "https://portal.prnewswire.com", "/contact-us/", "javascript:void(0)", "/contact-us/", "/contact-us/", "tel:+1-888-776-0942", "javascript:void(0)", "#", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/business-technology-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/financial-services-latest-news/", "/news-releases/general-business-latest-news/", "/news-releases/consumer-technology-latest-news/", "/news-releases/energy-latest-news/", "/news-releases/environment-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/telecommunications-latest-news/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/health-latest-news/", "/news-releases/sports-latest-news/", "/news-releases/travel-latest-news/", "/news-releases/multicultural-latest-news/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/products/all-products/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/contact-us/#general", "/request-a-demo/", "/contact-us/#editorial", "/contact-us/#partnerships", "/contact-us/#media", "/contact-us/#worldwide", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/novavax-announces-positive-results-of-covid-19-vaccine-in-pediatric-population-of-prevent-19-phase-3-clinical-trial-301480238.html", "/in/news-releases/novavax-announces-positive-results-of-covid-19-vaccine-in-pediatric-population-of-prevent-19-phase-3-clinical-trial-838128457.html", "/news-releases/novavax-anuncia-resultados-positivos-de-la-vacuna-de-la-covid-19-en-ninos-en-el-ensayo-prevent-19-810872985.html", "/news-releases/novavax-gibt-positive-ergebnisse-des-impfstoffs-covid-19-in-der-padiatrischen-population-der-klinischen-phase-3-studie-prevent-19-bekannt-879932083.html", "#", "/news/novavax%2C-inc./", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", null, "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3652379960&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D2201495428%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395363-1%2526h%253D1255159614%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DThe%252BNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DThe%2BNew%2BEngland%2BJournal%2Bof%2BMedicine&a=The+New+England+Journal+of+Medicine", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3245167637&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D1601107271%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3432645-1%2526h%253D3389525956%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3418278-1%252526h%25253D4293825725%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3397167-1%25252526h%2525253D2118831841%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fir.novavax.com%252525252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%25252526a%2525253Dconditional%2525252Bmarketing%2525252Bauthorization%252526a%25253DEuropean%25252BUnion%2526a%253DEuropean%252BUnion%26a%3DEuropean%2BCommission&a=Comisi%C3%B3n+Europea", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2811542486&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D2438596594%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-03-Medicines-and-Healthcare-Products-Regulatory-Agency-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine-in-Great-Britain%26a%3DMedicines%2Band%2BHealthcare%2Bproducts%2BRegulatory%2BAgency&a=Agencia+Reguladora+de+Medicamentos+y+Productos+Sanitarios", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2819954396&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D757336834%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3432645-1%2526h%253D2742482411%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3418278-1%252526h%25253D3156131270%252526u%25253Dhttps%2525253A%2525252F%2525252Fir.novavax.com%2525252F2021-12-20-World-Health-Organization-Grants-Second-Emergency-Use-Listing-for-Novavax-COVID-19-Vaccine%252526a%25253DWorld%25252BHealth%25252BOrganization%2526a%253DWorld%252BHealth%252BOrganization%26a%3DWorld%2BHealth%2BOrganization&a=Organizaci%C3%B3n+Mundial+de+la+Salud", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2707595385&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D1829805745%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3398108-1%2526h%253D1075217627%2526u%253Dhttps%25253A%25252F%25252Fprotect-us.mimecast.com%25252Fs%25252F0gHHC82A7pCjjZZvcwd3d-%25253Fdomain%25253Dnovavax.com%2526a%253Dnovavax.com%25252Fevents%26a%3Dnovavax.com%252Fevents&a=novavax.com%2Fevents", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3162182553&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D467849857%26u%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2116185%253Fquery%253Dfeatured_home%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=1609678534&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D3617137863%26u%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2107659%26a%3DNEJM&a=NEJM", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2486382758&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D3964594936%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395501-1%2526h%253D2463599076%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3392093-1%252526h%25253D203886192%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3387216-1%25252526h%2525253D3917401194%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3260461-1%2525252526h%252525253D2897486098%2525252526u%252525253Dhttp%25252525253A%25252525252F%25252525252Fwww.novavax.com%25252525252F%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=2359150338&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D105479535%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395501-1%2526h%253D4221703946%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3392093-1%252526h%25253D1222342448%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3387216-1%25252526h%2525253D3606837610%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3260461-1%2525252526h%252525253D1316526774%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3158017-1%252525252526h%25252525253D500821283%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Ftwitter.com%2525252525252FNovavax%252525252526a%25252525253DTwitter%2525252526a%252525253DTwitter%25252526a%2525253DTwitter%252526a%25253DTwitter%2526a%253DTwitter%26a%3DTwitter&a=Twitter", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3362115572&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D2733326919%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395501-1%2526h%253D853375093%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3392093-1%252526h%25253D1325598136%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3387216-1%25252526h%2525253D2935962557%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3260461-1%2525252526h%252525253D1508558197%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3158017-1%252525252526h%25252525253D3702938248%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fwww.linkedin.com%2525252525252Fcompany%2525252525252Fnovavax%2525252525252F%252525252526a%25252525253DLinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%252526a%25253DLinkedIn%2526a%253DLinkedIn%26a%3DLinkedIn&a=LinkedIn", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=1649886954&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D1486889287%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395501-1%2526h%253D3574403071%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3392093-1%252526h%25253D64626343%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3387216-1%25252526h%2525253D844488893%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3367039-1%2525252526h%252525253D3348182013%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fwww.instagram.com%25252525252Fnovavax%25252525252F%2525252526a%252525253DInstagram%25252526a%2525253DInstagram%252526a%25253DInstagram%2526a%253DInstagram%26a%3DInstagram&a=Instagram", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=772684240&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D3738538262%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3395501-1%2526h%253D1061571609%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3392093-1%252526h%25253D2234833677%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3387216-1%25252526h%2525253D4091724087%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fwww.facebook.com%252525252FNovavax%252525252F%25252526a%2525253DFacebook%252526a%25253DFacebook%2526a%253DFacebook%26a%3DFacebook&a=Facebook", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=3701513667&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D107092519%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=178454868&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D56116919%26u%3Dhttp%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com", "/cdn-cgi/l/email-protection#dbb2a99bb5b4adbaadbaa3f5b8b4b6", "/cdn-cgi/l/email-protection#a5c4d7cadce5d6cac9c0c7d0d7dcd1d7cad0d18bc6cac8", "/cdn-cgi/l/email-protection#e18c84858880a18f8e9780978099cf828e8c", "https://c212.net/c/link/?t=0&l=es&o=3440781-1&h=519295000&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D2800990811%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/biotechnology-list/", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "tel:Cision%20Distribution%20888-776-0942", "javascript://Chat", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "https://twitter.com/PRNewswire", "https://www.facebook.com/PR-Newswire-26247320522/", "https://www.linkedin.com/company/pr-newswire/", "/products/communications-cloud/", "/products/marketing/", "/products/public-relations/", "/products/ir-compliance/", "/products/agency/", "https://www.smallbusinesspr.com/request_information", "/products/all-products/", "https://prnewswire.mediaroom.com/index.php", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "/contact-us/prnewswire-partners/", "/contact-us/become-a-partner/", "https://www.cision.com/careers/", "https://www.cision.com/about/accessibility/", "https://www.prnasia.com/", "https://prnewswire.com.br/", "https://www.newswire.ca/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/fi/lehdistotiedotteet/", "/fr/communiques-de-presse/", "/de/pressemitteilungen/", "/in/news-releases/", "/il/news-releases/", "/it/comunicati-stampa/", "https://prnewswire.com.mx/", "/ae/news-releases/", "https://www.prnewswire.com/ae/ar/news-releases/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/es/comunicados-de-prensa/", "/sv/pressmeddelanden/", "https://www.prnewswire.co.uk/", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "/contact-us", "/products/overview", "https://prnewswire.mediaroom.com/index.php", "", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "tel:Cision%20Distribution%20Helpline", "/terms-of-use/", "/privacy-policy/", "/prn-information-security-policy/", "/sitemap/", "/rss/", "/cookie-settings/", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "javascript://Chat"]}